DK2437744T3 - Modulering af KCNQ-kaliumkanalaktivitet til behandling af psykiatriske lidelser og symptomerne deraf - Google Patents
Modulering af KCNQ-kaliumkanalaktivitet til behandling af psykiatriske lidelser og symptomerne deraf Download PDFInfo
- Publication number
- DK2437744T3 DK2437744T3 DK10784089.4T DK10784089T DK2437744T3 DK 2437744 T3 DK2437744 T3 DK 2437744T3 DK 10784089 T DK10784089 T DK 10784089T DK 2437744 T3 DK2437744 T3 DK 2437744T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- potassium channel
- channel activity
- kcnq
- schizophrenia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (12)
1. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse i behandling af et negativt symptom på skizofreni hos en patient med behov derfor, hvori forbindelsen er valgt blandt Linopirdine, XE991 og DMP543. 5
2. Anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, i fremstillingen af et medikament til behandling af et negativt symptom på skizofreni hos en patient med behov derfor, hvori forbindelsen er valgt blandt Linopirdine, XE991 og DMP543.
3. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge krav 1, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, ifølge krav 2, hvori forbindelsen blokerer eller lukker KCNQ-(Kv7)-kaliumkanalen.
4. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge 15 krav 1, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet ifølge krav 2, hvori det negative symptom er valgt fra en gruppe bestående af afstumpethed, manglende motivation, anhedoni, nedsat tale, social tilbagetrækning, manglende energi, og apati.
5. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge ethvert af kravene 1 eller 4, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, ifølge ethvert af kravene 2 eller 4, hvori forbindelsen yderligere behandler et kognitivt symptom på skizofreni hos patienten.
6. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge krav 5, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, ifølge krav 5, hvori det behandlede, kognitive symptom indbefatter et symptom valgt fra en gruppe bestående af dårlig handlekraftsfunktion, tab af opmærksomhed og fokus, opfattelsesevnemangler, indlæringsvanskeligheder, arbejdshukommelsemangler, og 30 problemer med kort- og langtidshukommelsen.
7. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge ethvert af kravene 1 eller 3 til 6, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, ifølge ethvert af kravene 2 til 6 yderligere omfattende 35 administrering af en effektiv mængde af en anden forbindelse til behandling af skizofreni.
8. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge ifølge krav 7, hvori den anden forbindelse til behandling af skizofreni er valgt fra en gruppe valgt blandt chlorpromazin, haloperidol, fluphenazin, promazin, sulpirid, clozapin, sertindol, amisulprid, zotepin, paliperidon, risperidon, aripiprazol, lamotrigin, quetiapin, perphenazin, flupenthixol, ziprasidon, olanzapin, lithium og valproinsyre. 5
9. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge krav 7 eller 8, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)- kaliumkanalaktivitet, ifølge krav 7 eller 8, hvori den anden forbindelse administreres samtidigt med forbindelsen, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet. 10
10. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge krav 7 eller 8, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)- kaliumkanalaktivitet, ifølge krav 7 eller 8, hvori den anden forbindelse administreres før den effektive mængde af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, og 15 valgfrit, at patienten modstandsdygtig overfor behandling med den anden forbindelse.
11. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge krav 7 eller 8, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)- kaliumkanalaktivitet, ifølge krav 7 eller 8, hvori den anden forbindelse administreres efter 20 den effektive mængde af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet.
12. Forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, til anvendelse ifølge krav 7, eller anvendelse af en forbindelse, som inhiberer KCNQ-(Kv7)-kaliumkanalaktivitet, ifølge krav 7, hvori den anden forbindelse behandler et kognitivt symptom på skizofreni hos 25 patienten, eller den anden forbindelse behandler et positivt symptom på skizofreni hos patienten.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21770609P | 2009-06-03 | 2009-06-03 | |
| PCT/US2010/037246 WO2010141712A2 (en) | 2009-06-03 | 2010-06-03 | Modulation of kcnq potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2437744T3 true DK2437744T3 (da) | 2015-07-27 |
Family
ID=43298512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10784089.4T DK2437744T3 (da) | 2009-06-03 | 2010-06-03 | Modulering af KCNQ-kaliumkanalaktivitet til behandling af psykiatriske lidelser og symptomerne deraf |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9017735B2 (da) |
| EP (1) | EP2437744B1 (da) |
| JP (1) | JP5714572B2 (da) |
| AU (1) | AU2010256541B2 (da) |
| CA (1) | CA2760825C (da) |
| DK (1) | DK2437744T3 (da) |
| WO (1) | WO2010141712A2 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170304281A1 (en) * | 2016-04-21 | 2017-10-26 | Loyola University Of Chicago | Methods of using potassium channel inhibitors (blockers) for fluid resuscitation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262081B1 (en) * | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
| EP1147134B1 (en) * | 1999-01-26 | 2006-10-11 | Neurosearch A/S | Novel potassium channels and genes encoding these potassium channels |
| CA2390101A1 (en) * | 1999-11-06 | 2001-05-17 | Albert Shulman | A method of treating substance addiction |
| CA2412208C (en) | 2000-06-29 | 2009-08-18 | Neurosearch A/S | Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators |
| JP2006514917A (ja) * | 2002-07-09 | 2006-05-18 | アルファ リサーチ グループ， エルエルシー | パーキンソン病および遅発性ジスキネジーの処置のための組成物および方法 |
| GT200500063A (es) * | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| UA89503C2 (uk) * | 2004-09-13 | 2010-02-10 | Х. Луннбек А/С | Заміщені похідні аніліну |
| US7091202B2 (en) * | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| EP1828413A1 (en) * | 2004-12-24 | 2007-09-05 | Ares Trading S.A. | Compositions and methods for treating mental disorders |
-
2010
- 2010-06-03 JP JP2012514126A patent/JP5714572B2/ja active Active
- 2010-06-03 EP EP10784089.4A patent/EP2437744B1/en active Active
- 2010-06-03 WO PCT/US2010/037246 patent/WO2010141712A2/en active Application Filing
- 2010-06-03 DK DK10784089.4T patent/DK2437744T3/da active
- 2010-06-03 AU AU2010256541A patent/AU2010256541B2/en active Active
- 2010-06-03 US US12/793,330 patent/US9017735B2/en active Active
- 2010-06-03 CA CA2760825A patent/CA2760825C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US9017735B2 (en) | 2015-04-28 |
| JP2012528881A (ja) | 2012-11-15 |
| CA2760825C (en) | 2017-07-11 |
| US20100310681A1 (en) | 2010-12-09 |
| JP5714572B2 (ja) | 2015-05-07 |
| AU2010256541A2 (en) | 2011-12-15 |
| AU2010256541A1 (en) | 2011-12-08 |
| AU2010256541B2 (en) | 2016-03-10 |
| EP2437744A2 (en) | 2012-04-11 |
| EP2437744A4 (en) | 2012-11-21 |
| EP2437744B1 (en) | 2015-06-03 |
| CA2760825A1 (en) | 2010-12-09 |
| WO2010141712A9 (en) | 2011-04-21 |
| WO2010141712A2 (en) | 2010-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7069253B2 (ja) | 統合失調症を治療するための２－（（１－（２（４－フルオロフェニル）－２－オキソエチル）ピペリジン－４－イル）メチル）イソインドリン－１－オン | |
| KR20180021693A (ko) | 신경퇴행성 질환을 치료하는 조성물 및 방법 | |
| KR20090087009A (ko) | 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법 | |
| JP2023523569A (ja) | 神経学的および精神障害の治療方法 | |
| WO2021016369A1 (en) | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder | |
| US20170049777A1 (en) | Compositions, methods and uses for the treatment of diabetic neuropathies | |
| AU2024204716A1 (en) | Treatment of alopecia areata | |
| JP2019516699A (ja) | 純粋な５−ｈｔ６受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤の組合せ | |
| JP6606298B2 (ja) | 純粋な５−ｈｔ６受容体アンタゴニストのｎｍｄａ受容体アンタゴニストとの組合せ | |
| DK2437744T3 (da) | Modulering af KCNQ-kaliumkanalaktivitet til behandling af psykiatriske lidelser og symptomerne deraf | |
| US9339500B2 (en) | Methods of treating vasomotor symptoms | |
| JP7556031B2 (ja) | 認知症患者の行動心理学的症状の治療 | |
| US20230000859A1 (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| RU2508106C2 (ru) | Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии | |
| US20050130987A1 (en) | Methods of treating vasomotor symptoms | |
| RU2508096C2 (ru) | Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии | |
| WO2014059346A1 (en) | Methods for the treatment of conditions involving dopamine through administration of piperazine compounds | |
| EA040638B1 (ru) | Фармацевтический состав, содержащий 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения психоневрологического заболевания или расстройства сна, способ лечения психоневрологического заболевания или расстройства сна, таблетка и набор | |
| JP2007515395A (ja) | 血管運動症状の治療方法 |